Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12 Week Open Label, Parallel Group, Comparative, Multicentric Phase III Study to Assess Efficacy and Safety of Metered Dose Buccal Insulin Spray versus Rapid Insulin s.c. on subjects with type II Diabetes who are inadequately controlled i.e. HbA1C 6.5 to 8.5 while on Oral Anti- Diabetic Agents - BUCLAR

X
Trial Profile

A 12 Week Open Label, Parallel Group, Comparative, Multicentric Phase III Study to Assess Efficacy and Safety of Metered Dose Buccal Insulin Spray versus Rapid Insulin s.c. on subjects with type II Diabetes who are inadequately controlled i.e. HbA1C 6.5 to 8.5 while on Oral Anti- Diabetic Agents - BUCLAR

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Jul 2013 Status changed from active, no longer recruiting to completed.
    • 10 Jul 2013 Results published in Generex Biotechnology Corporation Media Release.
    • 12 Nov 2012 New source identified and integrated (Clinical Trials Registry - India CTRI2012-09-003033).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top